A Phase 4 interventional study of ranibizumab and Conbercept in Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2017-11-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 113th largest by enrollment of the 124 interventional ones that give a count, is one of 3 that started in 2016, is one of 33 in phase 4, and was the 102nd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 53rd largest by enrollment of the 56 interventional ones that give a count, is the only one that started in 2016, is one of 18 in phase 4, and was the 41st registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular age-related macular degeneration
This prospective, randomized, open label study enrolled patients with neovascular AMD who were naïve to anti-VEGF therapy or have not received intravitreal anti-VEGF therapy for the previous 3 months. Patients were randomized in two treatment arms for 3 months:
Plasma VEGF concentration was measured by a blinded laboratory using Quantikine® ELISA kits. Serum ranibizumab and conbercept concentration will be determined using validated ELISA assay.
The study was divided into 2 stages: the 1st initial feasibility stage with 6 patients per arm (12 patients in total) to verify SD for sample size justification and 2nd stage to confirm the findings with justified sample size.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For both eyes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three monthly injections of 0.5mg Ranibizumab
Drug: ranibizumab
Three monthly injections of 0.5mg Conbercept
Drug: Conbercept
Also known as: Lucentis
Also known as: Langmu
Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day)
Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after first injection at Visit 5 (Day 8 +/- 1 day).Blood sample was collected for systemic VEGF. VEGF was measured by a blinded laboratory using ELISA kits.
Time frame: Baseline, Visit 5 (Day 8 +/- 1 day)
Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day)
Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after third injection at Visit 10 (Day 67 +/- 1 day). Blood sample was collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits.
Time frame: Baseline, Visit 10 (Day 67 +/- 1 day)
Plasma VEGF Concentration at Baseline, Visit 2, 3, 4, 5, 6 After 1st Injection
Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit Visit 2, 3, 4, 5, 6 after 1st injection
Time frame: Baseline, Visit 2, 3, 4, 5, 6
Plasma VEGF Concentration at Baseline, Visit 7, 8, 9, 10, 11 After 3rd Injection
Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit 7, 8, 9, 10, 11 after 3rd injection
Time frame: Baseline, Visit 7, 8, 9, 10, 11
| Milestone | Ranibizumab 0.5 mg | Conbercept 0.5 mg |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 5 |
| Not completed | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after first injection at Visit 5 (Day 8 +/- 1 day).Blood sample was collected for systemic VEGF. VEGF was measured by a blinded laboratory using ELISA kits.
| pg/mL | Ranibizumab 0.5 mg | Conbercept 0.5 mg |
|---|---|---|
| Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After First Injection at Visit 5 (Day 8 +/- 1 Day) | 5.720 ± 9.5547 | -25.833 ± 22.8145 |
Change from baseline in plasma Vascular endothelial growth factor (VEGF) concentration after third injection at Visit 10 (Day 67 +/- 1 day). Blood sample was collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits.
| pg/mL | Ranibizumab 0.5 mg | Conbercept 0.5 mg |
|---|---|---|
| Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration After Third Injection at Visit 10 (Day 67 +/- 1 Day) | -0.100 ± 17.4799 | -22.220 ± 12.9239 |
Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit Visit 2, 3, 4, 5, 6 after 1st injection
| pg/mL | Ranibizumab 0.5 mg | Conbercept 0.5 mg |
|---|---|---|
| Baseline | 31.400 ± 6.3816 | 42.200 ± 23.4269 |
| Visit 2 (Day 1) | 30.958 ± 19.9813 | 14.920 ± 12.4920 |
| Visit 3 (Day 2 +/- 1) | 36.517 ± 19.2783 | 24.590 ± 39.2435 |
| Visit 4 (Day 4 +/- 1) | 29.150 ± 5.5587 | 7.213 ± 4.9250 |
| Visit 5 (Day 8 +/- 1) | 37.000 ± 4.7979 | 19.075 ± 4.5051 |
| Visit 6 (Day 30 +/- 4) | 27.092 ± 13.2356 | 25.270 ± 15.0967 |
Blood sample will be collected for systemic VEGF. VEGF will be measured by a blinded laboratory using ELISA kits. Baseline, Visit 7, 8, 9, 10, 11 after 3rd injection
| pg/mL | Ranibizumab 0.5 mg | Conbercept 0.5 mg |
|---|---|---|
| Baseline | 36.250 ± 11.8610 | 36.520 ± 19.2278 |
| Visit 7 (Day 60 +/- 4) | 34.383 ± 12.7727 | 5.720 ± 2.1690 |
| Visit 8 (Day 61 +/- 1) | 46.533 ± 48.1293 | 6.820 ± 4.6287 |
| Visit 9 (Day 63 +/- 1) | 54.067 ± 40.2585 | 8.070 ± 4.6452 |
| Visit 10 (Day 67 +/- 1) | 36.150 ± 25.4399 | 14.300 ± 9.6690 |
| Visit 11 (Day 90 +/- 4) | 45.067 ± 18.0828 | 56.020 ± 27.0819 |
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | — | 0/6 (0%) | 1/6 (16.7%) |
| Conbercept 0.5 mg | — | 2/6 (33.3%) | 3/6 (50%) |
| Event | Ranibizumab 0.5 mg | Conbercept 0.5 mg |
|---|---|---|
| Infectious pneumoniaInfections and infestations | 0/6 | 1/6 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/6 | 1/6 |
| Fracture of jawInjury, poisoning and procedural complications | 0/6 | 1/6 |
| Fracture of ribInjury, poisoning and procedural complications | 0/6 | 1/6 |
| Pulmonary contusionInjury, poisoning and procedural complications | 0/6 | 1/6 |
| Thoracic injuryInjury, poisoning and procedural complications | 0/6 | 1/6 |
| COPDRespiratory, thoracic and mediastinal disorders | 0/6 | 1/6 |
| Event | Ranibizumab 0.5 mg | Conbercept 0.5 mg |
|---|---|---|
| DizzinessEar and labyrinth disorders | 0/6 | 1/6 |
| Conjunctival congestionEye disorders | 0/6 | 1/6 |
| Upper respiratory infectionInfections and infestations | 1/6 | 1/6 |
| HeadacheNervous system disorders | 0/6 | 1/6 |
| MigraineNervous system disorders | 1/6 | 0/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 1/6 |
| Age, Continuous(years) | Ranibizumab 0.5 mg | Conbercept 0.5 mg | Total |
|---|---|---|---|
| Mean | 65.3 ± 5.50 | 69.3 ± 8.41 | 67.3 ± 7.09 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg | Conbercept 0.5 mg | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 6 | 5 | 11 |
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Jan 2016 to primary completion in Jul 2016, 5 months.
Results were first posted in Nov 2017, 1 year 4 months after primary completion.
Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 5 months is below that.
Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab